U.S., March 1 -- ClinicalTrials.gov registry received information related to the study (NCT06852807) titled '18F-mFBG PET Imaging in the Evaluation of Neuroblastoma' on Feb. 04.
Brief Summary: The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with neuroblastoma.
Study Start Date: Feb. 04
Study Type: OBSERVATIONAL
Condition:
Neuroblastoma
Intervention:
DRUG: 18F-MFBG
Patients with neuroblastoma malignancies receive 5.55 MBq/kg of 18F-MFBG intravenously followed by PET/CT or PET/MR after 60min of injection.
Recruitment Status: RECRUITING
Sponsor: First Affiliated Hospital of Zhejiang University
Published by HT D...